These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16515971)

  • 1. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer.
    Xia G; Kumar SR; Hawes D; Cai J; Hassanieh L; Groshen S; Zhu S; Masood R; Quinn DI; Broek D; Stein JP; Gill PS
    J Urol; 2006 Apr; 175(4):1245-52. PubMed ID: 16515971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: relation to prognosis.
    Bonnesen B; Pappot H; Holmstav J; Skov BG
    Lung Cancer; 2009 Dec; 66(3):314-8. PubMed ID: 19324448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of vascular endothelial growth factor in primary superficial bladder cancer.
    Chow NH; Liu HS; Chan SH; Cheng HL; Tzai TS
    Anticancer Res; 1999; 19(5C):4593-7. PubMed ID: 10650816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer.
    Carrillo de Santa Pau E; Arias FC; Caso Peláez E; Muñoz Molina GM; Sánchez Hernández I; Muguruza Trueba I; Moreno Balsalobre R; Sacristán López S; Gómez Pinillos A; del Val Toledo Lobo M
    Cancer; 2009 Apr; 115(8):1701-12. PubMed ID: 19197998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.
    Rydén L; Jirström K; Bendahl PO; Fernö M; Nordenskjöld B; Stål O; Thorstenson S; Jönsson PE; Landberg G
    J Clin Oncol; 2005 Jul; 23(21):4695-704. PubMed ID: 16034044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.
    Liu L; Zhu D; Gao R; Guo H
    Urol Int; 2008; 81(1):72-6. PubMed ID: 18645275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer.
    Nakanishi R; Oka N; Nakatsuji H; Koizumi T; Sakaki M; Takahashi M; Fukumori T; Kanayama HO
    Urol Int; 2009; 83(1):98-106. PubMed ID: 19641368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Schlott T; Korabiowska M; Käthei N; Zöller G; Glaser F; Kunze E
    Anticancer Res; 2004; 24(5A):2745-56. PubMed ID: 15517881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Chlouverakis G; Vourvouhaki E; Turley H; Harris AL; Gatter KC
    Eur J Clin Invest; 2007 Nov; 37(11):878-86. PubMed ID: 17883421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression.
    Yang CC; Chu KC; Yeh WM
    Urol Oncol; 2004; 22(1):1-6. PubMed ID: 14969795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.
    Kopparapu PK; Boorjian SA; Robinson BD; Downes M; Gudas LJ; Mongan NP; Persson JL
    Anticancer Res; 2013 Jun; 33(6):2381-90. PubMed ID: 23749886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients.
    Ottaiano A; Franco R; Aiello Talamanca A; Liguori G; Tatangelo F; Delrio P; Nasti G; Barletta E; Facchini G; Daniele B; Di Blasi A; Napolitano M; Ieranò C; Calemma R; Leonardi E; Albino V; De Angelis V; Falanga M; Boccia V; Capuozzo M; Parisi V; Botti G; Castello G; Vincenzo Iaffaioli R; Scala S
    Clin Cancer Res; 2006 May; 12(9):2795-803. PubMed ID: 16675573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response.
    Rydén L; Stendahl M; Jonsson H; Emdin S; Bengtsson NO; Landberg G
    Breast Cancer Res Treat; 2005 Jan; 89(2):135-43. PubMed ID: 15692755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
    Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
    J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of VEGF and tumor angiogenesis in bladder cancer].
    Wang S; Xia T; Zhang Z; Kong X; Zeng L; Mi P; Xue Z
    Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):34-6. PubMed ID: 11831983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt.
    Imai N; Shikami M; Miwa H; Suganuma K; Hiramatsu A; Watarai M; Satoh A; Itoh M; Imamura A; Mihara H; Nitta M
    Br J Haematol; 2006 Dec; 135(5):673-82. PubMed ID: 17107349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
    Seto T; Higashiyama M; Funai H; Imamura F; Uematsu K; Seki N; Eguchi K; Yamanaka T; Ichinose Y
    Lung Cancer; 2006 Jul; 53(1):91-6. PubMed ID: 16697074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
    Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
    Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.
    Patel NS; Dobbie MS; Rochester M; Steers G; Poulsom R; Le Monnier K; Cranston DW; Li JL; Harris AL
    Clin Cancer Res; 2006 Aug; 12(16):4836-44. PubMed ID: 16914569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression.
    Crew JP; Fuggle S; Bicknell R; Cranston DW; de Benedetti A; Harris AL
    Br J Cancer; 2000 Jan; 82(1):161-6. PubMed ID: 10638984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.